News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology
Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today closed its transaction to acquire key assets from
Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022
QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their
Simulations Plus Releases GastroPlus® Version 9.8.3
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its
Agilent Opens Center of Excellence for Dissolution Products
Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the
Humana, USAA Launch New Medicare Advantage Plan Tailored to Veterans’ Needs
Humana Inc. (NYSE: HUM) and USAA Life Insurance Company (USAA Life) announced a new Medicare Advantage plan designed with veterans in mind to provide a robust coverage option that complements
Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of its first paper describing the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
GI Genius™ named to FORTUNE 2022 “Change the World” list
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2022 financial results on Wednesday, November 2nd, before the market opens. A conference call has been
Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close
Acadia Healthcare Announces Date for Third Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2022 results on Monday, October 31, 2022, after the close of the market. Acadia will conduct a
SISM Investors stuft Condor Technologies NV mit Buy-Rating ein
Ernest C. Schlotter, Senior Analyst bei SISM Investors mit Sitz in Zürich, Schweiz, und laut StarMine, einem ehemals zu Thomson Reuters gehörenden Unternehmen, ein Vier-Sterne-Analyst
EQS-News: Abivax: first US patient enrolled in global phase 3 program with obefazimod in ulcerative colitis